NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.60 +0.04 (+0.35 %) (As of 12/12/2018 12:01 PM ET)Previous Close$11.56Today's Range$11.47 - $11.7452-Week Range$10.10 - $32.20Volume9,677 shsAverage Volume721,798 shsMarket Capitalization$1.12 billionP/E Ratio-9.63Dividend YieldN/ABeta2.31 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts. Receive MNTA News and Ratings via Email Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MNTA Previous Symbol CUSIP60877T10 Webwww.momentapharma.com Phone617-491-9700 Debt Debt-to-Equity RatioN/A Current Ratio5.40 Quick Ratio5.40 Price-To-Earnings Trailing P/E Ratio-9.63 Forward P/E Ratio-4.31 P/E GrowthN/A Sales & Book Value Annual Sales$138.88 million Price / Sales6.57 Cash FlowN/A Price / Cash FlowN/A Book Value$4.90 per share Price / Book2.37 Profitability EPS (Most Recent Fiscal Year)($1.20) Net Income$-88,090,000.00 Net Margins-158.21% Return on Equity-44.72% Return on Assets-34.10% Miscellaneous Employees279 Outstanding Shares78,610,000Market Cap$1.12 billion OptionableOptionable Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions What is Momenta Pharmaceuticals' stock symbol? Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA." How were Momenta Pharmaceuticals' earnings last quarter? Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.63) by $0.18. The biotechnology company had revenue of $14.88 million for the quarter, compared to analyst estimates of $16.99 million. Momenta Pharmaceuticals had a negative net margin of 158.21% and a negative return on equity of 44.72%. The company's revenue for the quarter was down 38.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.44) EPS. View Momenta Pharmaceuticals' Earnings History. When is Momenta Pharmaceuticals' next earnings date? Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Momenta Pharmaceuticals. What price target have analysts set for MNTA? 3 analysts have issued twelve-month target prices for Momenta Pharmaceuticals' shares. Their forecasts range from $16.00 to $39.00. On average, they anticipate Momenta Pharmaceuticals' stock price to reach $30.00 in the next year. This suggests a possible upside of 158.6% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals. What is the consensus analysts' recommendation for Momenta Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals. What are Wall Street analysts saying about Momenta Pharmaceuticals stock? Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock: 1. According to Zacks Investment Research, "Momenta initiated a strategic review of its ongoing operations with the goal of reducing expenditure on its biosimilar portfolio, which should free up additional capital to fully fund its novel autoimmune portfolio.The company will now advance only two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira and M710, its proposed biosimilar to Eylea being developed in collaboration with Mylan. Momenta expects to file a biologics license application (BLA) for M923 with the FDA and plans to work to identify a commercialization partner for this product candidate. Momenta will restructure its executive team and reduce its workforce by approximately 50%. The cost savings from the restructuring plan should enable the company to redirect a meaningful portion of its resources toward novel drug candidates for the treatment of rare, immune-mediated diseases.Shares of the company have outperformed the industry in the year so far." (11/14/2018) 2. Stifel Nicolaus analysts commented, "We believe MNTA’s R&D day on 10/11 will be an important event as the company repositions itself as more of a traditional biotech refocusing its resources on its proprietary pipeline. We think management’s recent steps on restructuring is a testament to that and while the outcome of the strategic review did not get many investors excited, we think it was necessary ahead of R&D day. As we indicated in our resumption of coverage, we believe we are making an early call on MNTA given our bullishness on the promise of the FcRn class and think additional data at R&D day for its candidate, M281, could provide some incremental differentiation relative to other programs furthering our thesis it could be best-in-class and could offer modest near-term upside for the stock." (10/10/2018) Has Momenta Pharmaceuticals been receiving favorable news coverage? Media headlines about MNTA stock have trended positive this week, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. Who are some of Momenta Pharmaceuticals' key competitors? Some companies that are related to Momenta Pharmaceuticals include Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Rubius Therapeutics (RUBY), Spark Therapeutics (ONCE) and Autolus Therapeutics (AUTL). Who are Momenta Pharmaceuticals' key executives? Momenta Pharmaceuticals' management team includes the folowing people: Mr. Craig A. Wheeler, Pres, CEO & Exec. Director (Age 58)Dr. Ganesh Venkataraman Kaundinya, Co-Founder & Consultant (Age 51)Dr. Santiago Arroyo M.D., Ph.D., Chief Medical Officer & Sr. VP of Devel.Mr. Bruce A. Leicher, Consultant (Age 62)Mr. Scott M. Storer, Consultant Who are Momenta Pharmaceuticals' major shareholders? Momenta Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.42%), FMR LLC (15.00%), Vanguard Group Inc. (9.67%), Janus Henderson Group PLC (2.10%), Renaissance Technologies LLC (1.63%) and Bank of New York Mellon Corp (1.14%). Company insiders that own Momenta Pharmaceuticals stock include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Richard P Shea, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals. Which major investors are selling Momenta Pharmaceuticals stock? MNTA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Teachers Advisors LLC, VHCP Management II LLC, Tocqueville Asset Management L.P., Renaissance Technologies LLC, JPMorgan Chase & Co., JPMorgan Chase & Co. and Franklin Resources Inc.. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Anthony M Manning, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Jo Ann Beltramello, Santiago Arroyo, Scott M Storer and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals. Which major investors are buying Momenta Pharmaceuticals stock? MNTA stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Putnam Investments LLC, FMR LLC, Morgan Stanley, Bank of New York Mellon Corp, MetLife Investment Advisors LLC and Trexquant Investment LP. View Insider Buying and Selling for Momenta Pharmaceuticals. How do I buy shares of Momenta Pharmaceuticals? Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Momenta Pharmaceuticals' stock price today? One share of MNTA stock can currently be purchased for approximately $11.60. How big of a company is Momenta Pharmaceuticals? Momenta Pharmaceuticals has a market capitalization of $1.12 billion and generates $138.88 million in revenue each year. The biotechnology company earns $-88,090,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Momenta Pharmaceuticals employs 279 workers across the globe. What is Momenta Pharmaceuticals' official website? The official website for Momenta Pharmaceuticals is http://www.momentapharma.com. How can I contact Momenta Pharmaceuticals? Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected] MarketBeat Community Rating for Momenta Pharmaceuticals (NASDAQ MNTA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 455 (Vote Outperform)Underperform Votes: 450 (Vote Underperform)Total Votes: 905MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe MNTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNTA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: What is a Tariff?